Research ArticleClinical Studies

ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy

HYERA KIM, SEUNG TAE KIM, KWAI HAN YOO, JUNG YONG HONG, YOUNG SUK PARK, HO YEONG LIM and JOON OH PARK
In Vivo January 2021, 35 (1) 499-505; DOI: https://doi.org/10.21873/invivo.12284

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Overall survival after first-line gemcitabine and platinum according to ATM expression in patients with biliary tract cancer. ATM: Ataxiatelangiectasia mutated; CCC: cholangiocarcinoma; No.: number.

  • Figure 2.
    Figure 2.

    Progression-free survival after first-line gemcitabine and platinum according to ATM expression in patients with biliary tract cancer. ATM: Ataxia-telangiectasia mutated; CCC: cholangiocarcinoma; No.: number.

Tables

  • Table I.
  • Table II.
  • Table III.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy
HYERA KIM, SEUNG TAE KIM, KWAI HAN YOO, JUNG YONG HONG, YOUNG SUK PARK, HO YEONG LIM, JOON OH PARK
In Vivo Jan 2021, 35 (1) 499-505; DOI: 10.21873/invivo.12284
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords